SLC5A2 and hydrops fetalis: The CVD-REAL trial found that, compared with therapy using other antihyperglycemic drugs, initiation of an SGLT2 inhibitor was associated with a lower risk of death and HF in patients with and without CV disease (Cavender et al., 2018).